TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29016558

Group type: EXPERIMENTAL
Intervention: Insure FIT
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: OC FIT-CHEK
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Hemoccult II SENSA
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Insure FIT vs OC FIT-CHEK
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Insure FIT vs Hemoccult II SENSA
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: All tests
Number of subjects: 1006
Study: 24795163

Group type: EXPERIMENTAL
Intervention: TENS + TRTT
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Placebo TENS + TRTT
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control without active training
Number of subjects: 37
Study: 23128129

Group type: EXPERIMENTAL
Intervention: Veloderm (crystalline cellulose membrane)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vaseline gauze (control)
Number of subjects: 96
Study: 21461904

Group type: COMPARATOR
Intervention: Heavyweight mesh (HW)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Middleweight mesh (MW)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Lightweight composite polypropylene mesh (LW)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Titanised lightweight mesh (TLW)
Number of subjects: 600
Study: 17964764

Group type: EXPERIMENTAL
Intervention: Soleduc psycho-educational program (7 sessions, 1 hour each)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (non-specific psychosocial training)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Soleduc psycho-educational program (attendance of at least 7 modules)
Number of subjects: 220
Study: 16258165

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12786622

Group type: EXPERIMENTAL
Intervention: Arterial embolization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipiodol-targeted chemoembolization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of radioactive iodine mixed with Lipiodol
Number of subjects: 0
Study: 10758415

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 8931220

Group type: EXPERIMENTAL
Intervention: Intraportal PGE1 (250 or 500 micrograms/day for 3 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous PGE1 (720 micrograms/day for 3 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 26
Study: 1576624

Group type: EXPERIMENTAL
Intervention: Loracarbef (200‐mg capsule BID or 15 mg/kg/day suspension)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Penicillin VK (250‐mg capsule QID or 20 mg/kg/day suspension)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 116

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 116
Study: 2866759

Group type: EXPERIMENTAL
Intervention: Focal argon laser photocoagulation
Number of subjects: 2244

Group type: COMPARATOR
Intervention: Deferral of photocoagulation
Number of subjects: 2244
Study: 31672949

Group type: EXPERIMENTAL
Intervention: Smartphone Application Peer Support (SAPS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 29202347

Group type: EXPERIMENTAL
Intervention: Cigarette scavenging behavior (sharing a cigarette with a stranger, smoking a 'found' cigarette, smoking a previously used cigarette 'butt')
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Demographic and psychosocial factors associated with scavenging
Number of subjects: 227
Study: 27555883

Group type: EXPERIMENTAL
Intervention: Sensorimotor insole with a lateral pressure point
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control insole
Number of subjects: 34
Study: 24837447

Group type: EXPERIMENTAL
Intervention: Daily low-dose sildenafil (25 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22984008

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting
Number of subjects: 224
Study: 21215143

Group type: EXPERIMENTAL
Intervention: Oral glucose loading alone
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Oral standardized fat loading alone
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined glucose and fat loading
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 98
Study: 18673081

Group type: EXPERIMENTAL
Intervention: Uterine rupture (n=21)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-reassuring fetal status (n=63)
Number of subjects: 84
Study: 16163366

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 119
Study: 12200550

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 797

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 797
Study: 9584554

Group type: EXPERIMENTAL
Intervention: Vanceril treatment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 7638805

Group type: EXPERIMENTAL
Intervention: DeVilbiss 40 nebuliser
Number of subjects: 13

Group type: COMPARATOR
Intervention: DeVilbiss 45 nebuliser
Number of subjects: 13
Study: 2229497

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (1.5 x 10(6) IU) injected three times weekly for 3 weeks (cumulative dose of 13.5 million IU)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo injected three times weekly for 3 weeks
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 369645

Group type: EXPERIMENTAL
Intervention: Endolymphatic therapy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 146
Study: 30274756

Group type: EXPERIMENTAL
Intervention: Intra-articular hip injection (IAHI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fascia-iliaca compartment block (FICB)
Number of subjects: 120
Study: 25727055

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dialogical Exposure Therapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cold-submissive quadrant patients
Number of subjects: 138
Study: 24332365

Group type: EXPERIMENTAL
Intervention: Geographical momentary assessment (GMA)
Number of subjects: 27
Study: 22368260

Group type: EXPERIMENTAL
Intervention: Tablets containing actinidine (sucked three times a day for six days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo tablets without actinidine
Number of subjects: 14
Study: 20415152

Group type: EXPERIMENTAL
Intervention: Intra Coronary Shunt (ICS)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No Shunt
Number of subjects: 208
Study: 17938383

Group type: EXPERIMENTAL
Intervention: Self-measurement of blood pressure
Number of subjects: 430
Study: 15739120

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30‐45 mg/day
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Pioglitazone + Metformin (PIO+MET)
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Gliclazide (GLIC) 80‐320 mg/day
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Gliclazide + Metformin (GLIC+MET)
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Gliclazide (GLIC)
Number of subjects: 1880
Study: 12073296

Group type: EXPERIMENTAL
Intervention: Homozygous sickle cell disease children
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal control children
Number of subjects: 111
Study: 9701155

Group type: EXPERIMENTAL
Intervention: 5 mg Zn
Number of subjects: 205

Group type: COMPARATOR
Intervention: 1 mg Zn
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 7832079

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg once daily, SID group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Ofloxacin (300 mg in three divided doses, TID group)
Number of subjects: 85
Study: 3049876

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental) 1200 mg daily (400 mg t.i.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 30938567

Group type: EXPERIMENTAL
Intervention: Language education intervention (LEI) comprising cognitive, adaptive and rational thinking training
Number of subjects: 86

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 86
Study: 29362960

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination Exercise (CE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 27612501

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 27442397

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (1000 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 20
Study: 23294818

Group type: EXPERIMENTAL
Intervention: Active CES device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 21250801

Group type: EXPERIMENTAL
Intervention: Early surgery (Days 1 or 2)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Late surgery (Days 7-14)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Intermediate surgery (Days 3-6)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Early surgery (Days 1 or 2) for patients with hydrocephalus or Fisher Grade 3 or 4
Number of subjects: 1001
Study: 18574578

Group type: EXPERIMENTAL
Intervention: Saphenous nerve block (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo injection (Group II)
Number of subjects: 40
Study: 16861942

Group type: EXPERIMENTAL
Intervention: Triple therapy (tac/MMF/steroids)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Steroid stop
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: MMF stop
Number of subjects: 718
Study: 12643964

Group type: EXPERIMENTAL
Intervention: Inhibition of challenge-induced aversive emotional state
Number of subjects: 48

Group type: COMPARATOR
Intervention: Observation of emotional response
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inhibition of bodily sensations
Number of subjects: 48
Study: 11076430

Group type: EXPERIMENTAL
Intervention: Timolol gel 0.5% once daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Timolol aqueous solution 0.5% twice daily
Number of subjects: 52
Study: 9170340

Group type: EXPERIMENTAL
Intervention: N-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NO-synthase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-monomethyl-L-arginine (L-NMMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study: 8067787

Group type: EXPERIMENTAL
Intervention: Rice based oral rehydration therapy (ORT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: WHO ORS
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Rice based ORT
Number of subjects: 52
Study: 3287975

Group type: EXPERIMENTAL
Intervention: Cefotetan (single 2 g dose)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Cefoxitin (multiple 2 g doses)
Number of subjects: 269
Study: 31306216

Group type: EXPERIMENTAL
Intervention: IPX203
Number of subjects: 28

Group type: COMPARATOR
Intervention: IR CD-LD
Number of subjects: 28
Study: 28549445

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cryoprecipitate (Cryo)
Number of subjects: 100
Study: 24571126

Group type: EXPERIMENTAL
Intervention: Gla-300 (0.4 U/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gla-300 (0.6 U/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gla-100 (0.4 U/kg)
Number of subjects: 60
Study: 22474419

Group type: EXPERIMENTAL
Intervention: Add-on basal insulin therapy on top of oral agents
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study: 20213516

Group type: EXPERIMENTAL
Intervention: Anxiety item bank (15 items)
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Depressive symptoms item bank (14 items)
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Short forms and simulated computer adaptive tests
Number of subjects: 1529
Study: 17634484

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 794

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 794
Study: 16086921

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose before IRA stenting followed by 75 mg daily)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Ticlopidine (500 mg before IRA stenting followed by 250 mg twice daily)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 133

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 133
Study: 12126990

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (14 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nonabstinent smoking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Abstinent smoking
Number of subjects: 10
Study: 10102963

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate 240 mg b.d. plus furazolidone 100 mg b.d. plus clarithromycin 250 mg b.d. (Group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg b.d. plus amoxycillin 1000 mg b.d. (Group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Furazolidone 100 mg b.d. plus josamycin 1000 mg b.d. (Group C)
Number of subjects: 180
Study: 7521091

Group type: EXPERIMENTAL
Intervention: UroLume endoprosthesis
Number of subjects: 126
Study: 2572793

Group type: EXPERIMENTAL
Intervention: NG monomethyl‐L‐arginine (L‐NMMA) infusion into the brachial arteries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylcholine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glyceryl trinitrate infusion
Number of subjects: 0
Study: 1089474

Group type: EXPERIMENTAL
Intervention: Actinomycin D (Act D) and Vincristine (Vcr) for 1 year after surgery and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of Act D, Vcr, and cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four different drug combinations
Number of subjects: 0
Study: 30664816

Group type: EXPERIMENTAL
Intervention: Exercise program (2 days/week for 45 minutes over 6 months)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study: 28458129

Group type: EXPERIMENTAL
Intervention: Participant-selected song
Number of subjects: 12

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 12
Study: 25421981

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intensified pharmacological treatment
Number of subjects: 106
Study: 23171375

Group type: EXPERIMENTAL
Intervention: Sleep extension group (N = 13)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sleep maintenance group (N = 9)
Number of subjects: 22
Study: 22093417

Group type: EXPERIMENTAL
Intervention: Aripiprazole (5-25 mg/d)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Tiapride (100-500 mg/d)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 195
Study: 19300989

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 2
Study: 17005086

Group type: EXPERIMENTAL
Intervention: Yiweining (YWN) 200 ml, twice a day for 6 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gestrinone (GT) 2.5 mg, twice every week for 6 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Yiweining (YWN)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gestrinone (GT)
Number of subjects: 52
Study: 12775135

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg, once daily (FP200QD)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Montelukast 10 mg, once daily (MON10QD)
Number of subjects: 705
Study: 12903451

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-induced hypotension (MAP = 55 mmHg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-induced hypotension (MAP = 65 mmHg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normotension (Control group)
Number of subjects: 30
Study: 9185464

Group type: EXPERIMENTAL
Intervention: Diltiazem (1‐3 mcg.kg‐1.min‐1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no preventive diltiazem)
Number of subjects: 52
Study: 7952357

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Healon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid of higher viscosity (Healon GV)
Number of subjects: 0
Study: 3803417

Group type: EXPERIMENTAL
Intervention: Acipimox, 250 mg three times daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31541431

Group type: COMPARATOR
Intervention: Venetoclax (single doses of 10–500 mg or two cycles of 30–600 mg or placebo once daily for 7 days followed by a 21-day washout)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Continuous dosing with lower doses of venetoclax (e.g., 150 mg daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cyclic dosing with higher doses (e.g., 400 mg 1 week on/3 weeks off)
Number of subjects: 73
Study: 29752954

Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete fasting with placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete fasting with leptin replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leptin treatment vs placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leptin treatment in women with HA
Number of subjects: 0
Study: 27254034

Group type: EXPERIMENTAL
Intervention: YF vaccine with CYD‐TDV
Number of subjects: 787

Group type: COMPARATOR
Intervention: YF vaccine with placebo
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: CYD‐TDV after 2 injections
Number of subjects: 787

Group type: COMPARATOR
Intervention: CYD‐TDV after 2 injections (placebo group)
Number of subjects: 787
Study: 25083606

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) with food antigens administered directly to the duodenal mucosa.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Barrett's esophagus patients) resumed their previous diet.
Number of subjects: 36
Study: 22653459

Group type: EXPERIMENTAL
Intervention: Wound packing after incision and drainage
Number of subjects: 57

Group type: COMPARATOR
Intervention: No wound packing after incision and drainage
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Wound packing
Number of subjects: 57

Group type: COMPARATOR
Intervention: No wound packing
Number of subjects: 57
Study: 19926749

Group type: EXPERIMENTAL
Intervention: Papanicolaou-based rapid stain
Number of subjects: 126

Group type: COMPARATOR
Intervention: Wright-Giemsa-based rapid stain
Number of subjects: 126
Study: 17891480

Group type: EXPERIMENTAL
Intervention: 250‐mg caffeine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 200‐mg theanine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both caffeine and theanine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Neither caffeine nor theanine (placebo)
Number of subjects: 48
Study: 16025736

Group type: EXPERIMENTAL
Intervention: Benidipine 4 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12384193

Group type: EXPERIMENTAL
Intervention: Blinding status reported in RCTs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Double-blind RCTs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reporting practices of journals
Number of subjects: 40
Study: 10591231

Group type: EXPERIMENTAL
Intervention: Home visit by an experienced occupational therapist for assessment and modification of environmental hazards
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 530
Study: 8708496

Group type: EXPERIMENTAL
Intervention: Oral electrolyte solution made with rice syrup solids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparable glucose-based solution
Number of subjects: 0
Study: 1874580

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily - morning and 19h30
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily - morning and 22h30
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once daily at 19h30
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once daily at 22h30
Number of subjects: 1745

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 1745
Study: 7089790

Group type: EXPERIMENTAL
Intervention: Diagnostic flow charts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional patient-centered teaching
Number of subjects: 0
Study: 31306495

Group type: EXPERIMENTAL
Intervention: Dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31141062

Group type: EXPERIMENTAL
Intervention: Banded OAGB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-banded OAGB
Number of subjects: 20
Study: 28774488

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (colloid)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Lactated Ringer solution (crystalloid)
Number of subjects: 91
Study: 26452996

Group type: EXPERIMENTAL
Intervention: ALN-RSV01
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87